AI Summary & Key Takeaways
AI InsightHere, we report our experience with a Meril’s MyvalTM valve in a patient with severe aortic stenosis, peripheral artery disease, and a permanently implanted pacemaker.
📌 3 Key Takeaways
Özet
In light of because of its improved procedural and clinical success, transcatheter aortic valve implantation (TAVI) has become a significant alternative treatment option to surgery in patients with severe aortic valve stenosis. However, TAVI has its own contraindications and limitations, such as access route problems with transfemoral (TF) access being the safest and most widely used route. However, in patients in whom this route is unsuitable, axillary artery is the preferred alternative access route. Although TAVI valves are not licensed for axillary artery access, off-label use of balloon-expandable (Edwards Lifesciences, Irvine, CA, USA) and self-expandable (Evolute/CoreValve systems, Medtronic, Dublin, Ireland, as well as the Lotus valve system Boston Scientific Inc., Marlborough, MA, USA) valves have been reported. The Meril’s MyvalTM transaortic valve is a new-generation transaortic balloon-expandable valve, and transaxillary TAVI with this valve has not been reported previously. Here, we report our experience with a Meril’s MyvalTM valve in a patient with severe aortic stenosis, peripheral artery disease, and a permanently implanted pacemaker.